tbuckley/cabot-search huggingface dataset:
Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa
Authors: Jozefien Declercq, Sarah Gerlo, Sharon Van Nevel, Natalie De Ruyck, Gabriele Holtappels, Liesbeth Delesie, Els Tobback, Inés Lammens, Nikita Gerebtsov, Koen Sedeyn, Xavier Saelens, Bart N. Lambrecht, Philippe Gevaert, Linos Vandekerckhove, Stijn Vanhee
Journal: Science Translational Medicine (2024)

To prevent infection by respiratory viruses and consequently limit virus circulation, vaccines need to promote mucosal immunity. The extent to which the currently used messenger RNA (mRNA)–based COVID-19 vaccines induce mucosal immunity remains poorly characterized. We evaluated mucosal neutralizing antibody responses in a cohort of 183 individuals. Participants were sampled at several time points after primary adenovirus vector–based or mRNA-based COVID-19 vaccination and after mRNA-based booster vaccinations. Our findings revealed that repeated vaccination with mRNA boosters promoted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies in nasal secretions. Nasal and serum neutralizing antibody titers of both IgG and IgA isotypes correlated to one another. We investigated the source of these mucosal antibodies in a mouse model wherein mice received repeated mRNA vaccines for SARS-CoV-2. These experiments indicated that neutralizing antibody–producing cells reside in the spleen and bone marrow, whereas no proof of tissue homing to the respiratory mucosa was observed, despite the detection of mucosal antibodies. Serum transfer experiments confirmed that circulating antibodies were able to migrate to the respiratory mucosa. Collectively, these results demonstrate that, especially upon repeated vaccination, the currently used COVID-19 mRNA vaccines can elicit mucosal neutralizing antibodies and that vaccination might also stimulate mucosal immunity induced by previous SARS-CoV-2 infection. Moreover, migration of circulating antibodies to the respiratory mucosa might be a main mechanism. These findings advance our understanding of mRNA vaccine–induced immunity and have implications for the design of vaccine strategies to combat respiratory infections.
SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity
Authors: Ninaad Lasrado, Marjorie Rowe, Katherine McMahan, Nicole P. Hachmann, Jessica Miller, Catherine Jacob-Dolan, Jinyan Liu, Brookelynne Verrette, Kristin A. Gotthardt, Darren M. Ty, Juliana Pereira, Camille R. Mazurek, Amelia Hoyt, Ai-ris Y. Collier, Dan H. Barouch
Journal: Science Translational Medicine (2024)

Current COVID-19 vaccines provide robust protection against severe disease but minimal protection against acquisition of infection. Intramuscularly administered COVID-19 vaccines induce robust serum neutralizing antibodies (NAbs), but their ability to boost mucosal immune responses remains to be determined. In this study, we show that the XBB.1.5 messenger RNA (mRNA) boosters result in increased serum neutralization to multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in humans, including the dominant circulating variant JN.1. In contrast, we found that the XBB.1.5 mRNA booster did not augment mucosal NAbs or mucosal IgA responses, although acute SARS-CoV-2 XBB infection substantially increased mucosal antibody responses. These data demonstrate that current XBB.1.5 mRNA boosters substantially enhance peripheral antibody responses but do not robustly increase mucosal antibody responses. Our data highlight a separation between the peripheral and mucosal immune systems in humans and emphasize the importance of developing next-generation vaccines to augment mucosal immunity to protect against respiratory virus infections.
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy
Authors: Xiuting Liu, John M. Baer, Meredith L. Stone, Brett L. Knolhoff, Graham D. Hogg, Madeleine C. Turner, Yu-Lan Kao, Alyssa G. Weinstein, Faiz Ahmad, Jie Chen, Andrew D. Schmidt, Jeffrey A. Klomp, Heather Coho, Kayjana S. Coho, Silvia Coma, Jonathan A. Pachter, Kirsten L. Bryant, Liang-I Kang, Kian-Huat Lim, Gregory L. Beatty, David G. DeNardo
Journal: Science Translational Medicine (2024)

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that is often resistant to therapy. An immune suppressive tumor microenvironment (TME) and oncogenic mutations in KRAS have both been implicated as drivers of resistance to therapy. Mitogen-activated protein kinase (MAPK) inhibition has not yet shown clinical efficacy, likely because of rapid acquisition of tumor-intrinsic resistance. However, the unique PDAC TME may also be a driver of resistance. We found that long-term focal adhesion kinase (FAK) inhibitor treatment led to hyperactivation of the RAS/MAPK pathway in PDAC cells in mouse models and tissues from patients with PDAC. Concomitant inhibition of both FAK (with VS-4718) and rapidly accelerated fibrosarcoma and MAPK kinase (RAF-MEK) (with avutometinib) induced tumor growth inhibition and increased survival across multiple PDAC mouse models. In the TME, cancer-associated fibroblasts (CAFs) impaired the down-regulation of MYC by RAF-MEK inhibition in PDAC cells, resulting in resistance. By contrast, FAK inhibition reprogramed CAFs to suppress the production of FGF1, which can drive resistance to RAF-MEK inhibition. The addition of chemotherapy to combined FAK and RAF-MEK inhibition led to tumor regression, a decrease in liver metastasis, and improved survival in KRAS-driven PDAC mouse models. Combination of FAK and RAF-MEK inhibition alone improved antitumor immunity and priming of T cell responses in response to chemotherapy. These findings provided the rationale for an ongoing clinical trial evaluating the efficacy of avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in patients with PDAC and may suggest further paths for combined stromal and tumor-targeting therapies.
Characterization of clonal dynamics using duplex sequencing in donor-recipient pairs decades after hematopoietic cell transplantation
Authors: Masumi Ueda Oshima, Jacob Higgins, Isaac Jenkins, Timothy Randolph, Thomas Smith, Charles Valentine, Jesse Salk, Cecilia Yeung, Lan Beppu, Judy Campbell, Paul A. Carpenter, Stephanie J. Lee, Mary E. Flowers, Jerald P. Radich, Rainer Storb
Journal: Science Translational Medicine (2024)

After allogeneic hematopoietic cell transplantation (HCT), a very small number of donor stem cells reconstitute the recipient hematopoietic system, whereas the donor is left with a near-normal pool of stem cells. We hypothesized that the increased replicative stress on transplanted donor cells in the recipient could lead to the disproportionate proliferation of clonal hematopoiesis (CH) variants. We obtained blood samples from 16 related donor-recipient pairs at a median of 33.8 years (range: 6.6 to 45.7) after HCT, including the longest surviving HCT recipients in the world. For 11 of 16 pairs, a donor sample from the time of HCT was available for comparison. We performed ultrasensitive duplex sequencing of genes recurrently mutated in myeloid malignancies and CH, as well as a set of functionally neutral genomic regions representative of human genomic content at large. CH variants were observed in all donors, even those as young as 12 years old. Where donor pre-HCT sample was available, the average mutation rate in donors compared to recipients post-HCT was similar (2.0% versus 2.6% per year, respectively) within genes recurrently mutated in myeloid malignancies. Twenty-two (5.6%) of the 393 variants shared between paired donors and recipients post-HCT showed ≥10-fold higher variant allele frequency (VAF) in the recipient. A longer time since HCT was positively associated with the expansion of shared variant VAFs in the recipient. In conclusion, even decades after HCT, there does not appear to be widespread accelerated clonal expansion in the transplanted cells, highlighting the immense regenerative capacity of the human hematopoietic system.
<i>Cryptosporidium</i> lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacy
Authors: Nicola Caldwell, Caroline Peet, Peter Miller, Beatrice L. Colon, Malcolm G. Taylor, Mattia Cocco, Alice Dawson, Iva Lukac, Jose E. Teixeira, Lee Robinson, Laura Frame, Simona Seizova, Sebastian Damerow, Fabio Tamaki, John Post, Jennifer Riley, Nicole Mutter, Jack C. Hanna, Liam Ferguson, Xiao Hu, Michele Tinti, Barbara Forte, Neil R. Norcross, Peter S. Campbell, Nina Svensen, Flora C. Caldwell, Chimed Jansen, Vincent Postis, Kevin D. Read, Christopher D. Huston, Ian H. Gilbert, Beatriz Baragaña, Mattie C. Pawlowic
Journal: Science Translational Medicine (2024)

Cryptosporidiosis is a diarrheal disease caused by infection with Cryptosporidium spp. parasites and is a leading cause of death in malnourished children worldwide. The only approved treatment, nitazoxanide, has limited efficacy in this at-risk patient population. Additional safe therapeutics are urgently required to tackle this unmet medical need. However, the development of anti-cryptosporidial drugs is hindered by a lack of understanding of the optimal compound properties required to treat this gastrointestinal infection. To address this knowledge gap, a diverse set of potent lysyl-tRNA synthetase inhibitors was profiled to identify optimal physicochemical and pharmacokinetic properties required for efficacy in a chronic mouse model of infection. The results from this comprehensive study illustrated the importance of balancing solubility and permeability to achieve efficacy in vivo. Our results establish in vitro criteria for solubility and permeability that are predictive of compound efficacy in vivo to guide the optimization of anti-cryptosporidial drugs. Two compounds from chemically distinct series (DDD489 and DDD508) were identified as demonstrating superior efficacy and prioritized for further evaluation. Both compounds achieved marked parasite reduction in immunocompromised mouse models and a disease-relevant calf model of infection. On the basis of these promising data, these compounds have been selected for progression to preclinical safety studies, expanding the portfolio of potential treatments for this neglected infectious disease.
Predictors and Clinical Outcomes of True Mitral Stenosis in Patients Undergoing Transcatheter Aortic Valve Implantation
Authors: Mitsuki Yamaga, Masaki Izumo, Yukio Sato, Tatsuro Shoji, Daisuke Miyahara, Yoshikuni Kobayashi, Takahiko Kai, Taishi Okuno, Shingo Kuwata, Masashi Koga, Yasuhiro Tanabe, Yoshihiro J Akashi
Journal:  (2024)

Predictors of true degenerative mitral stenosis (MS) in patients with aortic stenosis who underwent transcatheter aortic valve implantation (TAVI) remain unknown. This study aimed to investigate the predictors and prognostic value of true degenerative MS in this population.
TCT-60 Intracardiac or Transesophageal Echocardiography for Left Atrial Appendage Occlusion: An Updated Systematic Review and Meta-Analysis
Authors: Kyriakos Dimitriadis, Eirini Beneki, Konstantinos Aznaouridis, Nikolaos Pyrpyris, Panagiotis Tsioufis, Christos Fragkoulis, Alexios Antonopoulos, Konstantina Aggeli
Journal: Journal of the American College of Cardiology (2024)
TCT-44 Angiographic and Clinical Impact of Balloon Inflation Time in Percutaneous Coronary Interventions With Sirolimus-Coated Balloon: A Subanalysis of the EASTBOURNE Study
Authors: Filippo Luca Gurgoglione, Dario Gattuso, Davide Donelli, Bernardo Cortese
Journal: Journal of the American College of Cardiology (2024)
TCT-479 Incomplete Resolution of Left Ventricular Outflow Tract Gradient After Alcohol Septal Ablation Is Predictive of Need for Reintervention in Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study
Authors: Kylie Duckworth, Nikhil Rao, Jessica Atkins, Christopher Nielsen, Kirsten Raby, Safanah Siddiqui, Valerian Fernandes
Journal: Journal of the American College of Cardiology (2024)
TCT-40 Sirolimus- vs. Paclitaxel-Coated Balloons for Treatment of Coronary Artery Disease
Authors: Pier Pasquale Leone, Gianmaria Calamita, Mauro Gitto, Francesco Tartaglia, Damiano Regazzoli, Antonio Mangieri, Gabriele Gasparini, Ottavia Cozzi, Marco Luciano Rossi, Bernhard Reimers, Antonio Colombo
Journal: Journal of the American College of Cardiology (2024)
TCT-501 Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Coronary In-Stent Restenosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: Ahmad Al-Abdouh, Dealla Samadi, Fares Sukhon, Mohammed Mhanna, Luai Madanat, Laith Alhuneafat, Mohammad Alqarqaz, Timir Paul, Amartya Kundu
Journal: Journal of the American College of Cardiology (2024)
TCT-503 Percutaneous Coronary Intervention of Lipid-Rich Plaques and Impact of Thrombus Burden on Late Acquired Stent Malapposition: A Substudy From the NIRVUS Trial
Authors: Manijeh Noori, Mikkel Hougaard, Akiko Maehara, Kirstine Hansen, Karsten Veien, Henrik Hansen, Julia Ellert, Anders Junker, Jens Trøan, Jens Lassen, Lisette Okkels Jensen
Journal: Journal of the American College of Cardiology (2024)
TCT-434 Clinical Outcomes After Scoring-Balloon Angioplasty and Sirolimus-Eluting Balloon Angioplasty for the Treatment of Diffuse, Small Vessel Coronary Artery Disease (SCA-DEB Study) (Clinicaltrials.Gov ID: NCT04101621)
Authors: Dobrin Vassilev, Niya Mileva, Panayot Panayotov, Ilter Pazardhykly, Gavril Stoev, Kiril Karamfiloff
Journal: Journal of the American College of Cardiology (2024)
TCT-483 One-Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus
Authors: Daria Feshchenko, Nikita Arablinskiy, Dmitry Vasiliev, Firdavs Shukurov, Artem Shanoyan, Oksana Drapkina
Journal: Journal of the American College of Cardiology (2024)
TCT-451 Plaque Changes and Vessel Remodeling After Balloon Angioplasty for De Novo Coronary Lesions Using Paclitaxel-Coated Balloons: A Serial IB-IVUS Study
Authors: Shelby Kerr, Shingo Minatoguchi, Chisato Kobayashi, Sho Kosokabe, Noriko Endo, Yuto Masuda, Genki Naruse, Takatomo Watanabe, Yoshihisa Yamada, Hiromitsu Kanamori, Hiroyuki Okura
Journal: Journal of the American College of Cardiology (2024)
TCT-472 A 4-Year Analysis of the National Readmissions Database to Determine Predictors for 90-Day Readmissions for Impella Support
Authors: Hiral Amin, Rohan Umrani, Shashank Gupta, Neethi Dasu, Yaser Khalid, Kirti Dasu
Journal: Journal of the American College of Cardiology (2024)
TCT-440 Angiography-Derived Radial Wall Strain Predicts Efficacy of Drug-Coated Balloon Angioplasty for De Novo Small Vessel Disease: Insights From the PEPCAD China SVD Study
Authors: Ke Xu, Xi Fu, Yizhe Wu, Zhiqing Wang, Miao Chu, Juying Qian, Ben He, Shengxian Tu, Linghong Shen, Junbo Ge
Journal: Journal of the American College of Cardiology (2024)
TCT-481 Renal Artery Imaging Through Long-Term Follow-up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program
Authors: Felix Mahfoud, David Kandzari, Kazuomi Kario, Michael Weber, Roland Schmieder, Konstantinos Tsioufis, Minglei Liu, Vanessa DeBruin, Michael Böhm
Journal: Journal of the American College of Cardiology (2024)
TCT-45 Catheter Ablation for Ventricular Tachycardia in Patients With Underlying Cardiomyopathy
Authors: Shafaqat Ali, Faryal Farooq, Manoj Kumar, Rafia Yasmine Khan, Thannon Alsaeed, Sanchit Duhan, Amro Taha, Vijaywant Brar, Hameem Changezi
Journal: Journal of the American College of Cardiology (2024)
TCT-458 Use of a Long Femoral Return Cannula Positioned in the Thoracic Aorta With VA-ECMO Resolves Differential Hypoxemia in a Preclinical Model of North South Syndrome
Authors: Navin Kapur, Lara Reyelt, Arik Stolyarov, Shreyas Bhave, Elena Mahmoudi, Kay Everett, Xiaoying Qiao, Lija Swain
Journal: Journal of the American College of Cardiology (2024)
TCT-35 Evaluating Regional Variation in Outcomes for Ruptured Thoracic Aortic Aneurysms Across the United States (2010-2020)
Authors: Zaid Abood, Raya Khraisat, Rayan Dastagir, Eric Weiss, Tanvir Bajwa, Suhail Allaqaband, M. Fuad Jan
Journal: Journal of the American College of Cardiology (2024)
TCT-466 Renal Artery Denervation Combined With Pulmonary Vein Isolation in Patients With Heart Failure and Atrial Fibrillation: A Randomized Trial Preliminary Results and Study Design
Authors: Tomasz Skowerski, Mariusz Skowerski, Iwona Wozniak-Skowerska, Andrzej Hoffmann, Mariusz Bałys, Andrzej Ochała, Zbigniew Gasior, Katarzyna Mizia-Stec, Grzegorz Smolka
Journal: Journal of the American College of Cardiology (2024)
TCT-452 Angio-Based Quantitative Fractional Ratio After Drug-Coated Balloon for De Novo Coronary Lesions: Potential Role of Single View-Based Analysis
Authors: Edoardo Oscar Genta, Stefano Galli, Stefano De Martini, Valentina Ardizzone, Cristina Ferrari, Sarah Troiano, Giovanni Teruzzi, Paolo Olivares, Carlo Maria Giacari, Bianca Ada Magnanini, Piero Montorsi
Journal: Journal of the American College of Cardiology (2024)
TCT-448 Real-World Application of Sirolimus-Coated Balloons in Acute Coronary Syndrome
Authors: Erick Marlon Avila Gil, Pablo Juan Salvadores, Jose Antonio Baz Alonso, Ricardo De La Rosa Bibiano, Victor Alfonso Jiménez Díaz, Andres Iñiguez Romo
Journal: Journal of the American College of Cardiology (2024)
TCT-442 Tissue Characteristics Can Predict Clinical Outcome in Stent-Less Percutaneous Coronary Intervention With Directional Coronary Atherectomy Followed by Drug-Coated Balloon: Insights From Histologic Analysis
Authors: Norihito Nakamura, Sho Torii, Yu Sato, Kazuki Aihara, Manabu Shiozaki, Ayako Yoshikawa, Yuji Ikari, Gaku Nakazawa
Journal: Journal of the American College of Cardiology (2024)
TCT-41 Paclitaxel-Coated Versus Sirolimus-Coated Balloon Angioplasty for Coronary Artery Disease: A Systematic Review and Meta-Analysis
Authors: Doosup Shin, Mandeep Singh, Evan Shlofmitz, Bruno Scheller, Azeem Latib, David Kandzari, Azfar Zaman, Darren Mylotte, Ali Dakroub, Sarah Malik, Koshiro Sakai, Matthew Cannata, Yasemin Ciftcikal, Emma Caron, Allen Jeremias, Jeffrey Moses, Richard Shlofmitz, Gregg Stone, Ziad Ali
Journal: Journal of the American College of Cardiology (2024)
TCT-489 Comparison of Tissue Characteristics of Restenosis After Coronary Interventions: Insights From Histologic Analysis After Directional Coronary Atherectomy
Authors: Norihito Nakamura, Sho Torii, Kazuki Aihara, Ken Miura, Yu Sato, Yuki Matsumoto, Manabu Shiozaki, Yuji Ikari, Gaku Nakazawa
Journal: Journal of the American College of Cardiology (2024)
TCT-454 Procedural Predictors of Optimal Angiographic Lesion Outcomes After Drug-Coated Balloon Treatment for De Novo Coronary Artery Disease
Authors: Dong Oh Kang, Bitna Kim, Jong-Seok Lee, Yong-Hyun Kim, Sang Yup Lim, Seong Hwan Kim, Jeong-Cheon Ahn, Ae-Young Her, Woo-Hyuk Song, Eun-Seok Shin, Sunwon Kim
Journal: Journal of the American College of Cardiology (2024)
TCT-441 Drug-Coated Balloon Versus Drug-Eluting Stent for Small Coronary Vessel Disease: A Systematic Review and Meta-Analysis
Authors: Marília Gobbo, Renan Sudo, Ancy Franco, Mable Pereira, Tanize Milbradt, Zeynep Bakir, Iago Pires, Gustavo Agostini, Stephen Akinfenwa, Denise Pellegrini, Paulo Caramori
Journal: Journal of the American College of Cardiology (2024)
TCT-540 Second-Generation Cryoballoon Ablation vs Contact-Force Sensing Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis
Authors: Irfan Ullah, Muhammad Ahmed, Faisal Aftab, Thakar Venjhraj, Aman Goyal, Muhammad Irfan, Abdul Wali Khan, Bernardo Cortese
Journal: Journal of the American College of Cardiology (2024)
TCT-480 Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program
Authors: Felix Mahfoud, Giuseppe Mancia, Robert Whitbourn, David Kandzari, Konstantinos Tsioufis, Flavio Ribichini, Faisal Sharif, Jiguang Wang, Michael Böhm
Journal: Journal of the American College of Cardiology (2024)
TCT-447 The Effectiveness of Combination Use of Cutting Balloon Followed by Drug Coated Balloon Compared With Drug Coated Balloon, Cutting Balloon, and Balloon Angioplasty
Authors: Manabu Shiozaki, Sho Torii, Kazuki Aihara, Yu Sato, Norihito Nakamura, Yuki Matsumoto, Gaku Nakazawa, Yuji Ikari
Journal: Journal of the American College of Cardiology (2024)
TCT-455 Quantitative Coronary Dissection Volume After Sirolimus or Paclitaxel Coated Balloon and Lumen Changes at 6 Months: Serial OCT Sub-study of TRANSFORM-I Trial
Authors: Akihiro Tobe, Kotaro Miyashita, Asahi Oshima, TsungYing Tsai, Jouke Dijkstra, Bernardo Cortese, Patrick Serruys, Yoshinobu Onuma, Faisal Sharif
Journal: Journal of the American College of Cardiology (2024)
TCT-502 Nicotine Inhibits Re-Endothelialization and Promotes Inflammation and Neoatherosclerosis After Drug-Eluting Stent Implantation in a Swine Model
Authors: Seok Oh, Juhan kim, Saleem Ahmad, Yu Jeong Jin, Mi Hyang Na, Munki Kim, Jeong Ha Kim, Dae Sung Park, Dae Young Hyun, Kyung Hoon Cho, Min Chul Kim, Doo Sun Sim, Young Joon Hong, Seung-won Lee, Youngkeun Ahn, Myung Ho Jeong
Journal: Journal of the American College of Cardiology (2024)
TCT-474 Adverse Events and Failure Modes Related to Impella CP: Insights From the FDA MAUDE Database
Authors: Kalyan Chitturi, Abhishek Chaturvedi, Ryan Wallace, Ilan Merdler, Brian Case, Hayder Hashim, Itsik Ben-Dor, Toby Rogers, Ron Waksman
Journal: Journal of the American College of Cardiology (2024)
TCT-446 Long-Term Outcomes and Impact of Diabetes Mellitus in Patients Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis
Authors: Gakuto Bando, Akihiro Ikuta, Hiroyuki Tanaka, Takeshi Tada, Kazushige Kadota
Journal: Journal of the American College of Cardiology (2024)
TCT-494 Between a Stent and a Hard Place: Insights Into Percutaneous Coronary Interventions and In-Stent Restenosis in Cancer Patients
Authors: Teodora Donisan, Oisin Galvin, Atefeh Ghorbanzadeh, Sunnia Chen, Joon Korleski, Hilda Mariana Gonzalez Bonilla, Ximin Fan, Bradley Lewis, Joerg Herrmann
Journal: Journal of the American College of Cardiology (2024)
TCT-473 Adverse Events and Failure Modes Related to Impella RP/RP Flex: Insights From the FDA MAUDE Database
Authors: Kalyan Chitturi, Ryan Wallace, Marta Lorente-Ros, Ilan Merdler, Abhishek Chaturvedi, Brian Case, Hayder Hashim, Itsik Ben-Dor, Toby Rogers, Ron Waksman
Journal: Journal of the American College of Cardiology (2024)
TCT-453 Comparison of “Predicted” Versus “Calculated” Flow Ratio (μFR) Acquired With Single-Angiographic View to Guide Drug-Coated Balloon Angioplasty in Coronary De-Novo Lesions
Authors: Stefano Galli, Edoardo Oscar Genta, Sarah Troiano, Stefano De Martini, Valentina Ardizzone, Giovanni Teruzzi, Paolo Olivares, Carlo Maria Giacari, Piero Montorsi
Journal: Journal of the American College of Cardiology (2024)
TCT-439 Temporal Trends in the Use of Drug-Coated Balloons in Poland: An Analysis Based on the National Registry
Authors: Rafal Januszek, Sylwia Iwańczyk, Wojciech Wojakowski, Zenon Huczek, Rafał Wolny, Adam Janas, Adrian Włodarczak, Maksymilian Opolski, Milosz Dziarmaga, Kamil Bujak, Michal Hawranek, Krzysztof Malinowski, Piotr Wacinski, Pawel Gasior, Piotr Niezgoda, Zbigniew Siudak, Bernardo Cortese, Wojtek Wanha
Journal: Journal of the American College of Cardiology (2024)
TCT-541 Gender Differences in Periprocedural Outcomes of Left Atrial Appendage Occlusion: A Systematic Review and Meta-Analysis
Authors: Kyriakos Dimitriadis, Nikolaos Pyrpyris, Eirini Beneki, Konstantinos Aznaouridis, Panagiotis Kostakis, Alexandros Koulouriotis, Christos Fragkoulis, Konstantina Aggeli
Journal: Journal of the American College of Cardiology (2024)
TCT-50 Statewide Quality Improvement Initiative to Increase Intracoronary Imaging Optimization in PCI: A Report From the BMC2 Registry
Authors: Ryan Madder, Devraj Sukul, Prasanthi Yelavarthy, Milan Seth, Elizabeth Pielsticker, John Gribar, Brett Wanamaker, Hitinder Gurm
Journal: Journal of the American College of Cardiology (2024)